Senate Dems Push Full Legalization as Trump Backs Rescheduling

Photo by Caleb Perez via Unsplash.

Senate Democrats put a full legalization bill back on the table on July 16, 2026, and the timing wasn't an accident. Sens. Cory Booker, Chuck Schumer, and Ron Wyden reintroduced the Cannabis Administration and Opportunity Act with 17 cosponsors just as the Trump administration's own marijuana policy effort was hitting a critical stretch of its DEA hearing process. Two very different federal approaches to cannabis are now moving on parallel tracks at the same time, and that's not a coincidence either.

This marks the third time CAOA has been filed since 2022, and the first two attempts never even got a committee vote, let alone floor time. So there's reason for skepticism about whether round three ends any differently. But the bill's reintroduction isn't just a symbolic gesture recycled for headlines -- it's a direct challenge to the administration's narrower plan to reclassify marijuana under Schedule III rather than remove it from the Controlled Substances Act altogether. If CAOA ever became law, it wouldn't complement the DEA's rescheduling proceeding. It would make that entire proceeding legally irrelevant.

What's Actually in the CAOA

Photo by Terrance Barksdale via Pexels.

CAOA doesn't tinker with cannabis's schedule -- it erases the category entirely. The bill would strike marijuana from the Controlled Substances Act altogether, a legal move known as descheduling, which is a fundamentally different action than shifting a substance to a lower schedule. Once signed into law, the attorney general would have 180 days to finalize the rule that formally removes cannabis from the CSA, giving federal agencies a hard deadline to update enforcement guidance and internal policy.

The bill also reaches well beyond drug scheduling into the lives of people already convicted under the old regime. It creates a federal expungement process and restores access to housing assistance, employment opportunities, and civil rights that many people lost because of marijuana convictions -- addressing the retroactive harm that rescheduling alone would leave completely untouched.

On the money side, CAOA sets up a federal excise tax structure that scales with business size. Small and mid-sized producers would start at a 5% rate, climbing to 12.5% after five years, while larger cannabis businesses would start at 10% and could eventually be taxed as high as 25%. The bill also takes aim at workplace fallout from federal marijuana testing, barring most agencies from testing employees for cannabis use, though it carves out exceptions for law enforcement and national security positions where testing would continue.

Perhaps most consequential for the existing industry, CAOA directs FinCEN to update its banking guidance for cannabis businesses and opens SBA loan programs to companies currently locked out of traditional federal lending because of marijuana's Schedule I status. Those two provisions alone would address problems that rescheduling to Schedule III, on its own, simply doesn't solve.

Who's Behind the Bill

Photo by khezez | خزاز via Pexels.

Cory Booker, Chuck Schumer, and Ron Wyden are the lead sponsors, and their names track with the bill's history -- all three have carried versions of this legislation in previous sessions. This time they're backed by 17 original cosponsors, including Bennet, Fetterman, Gillibrand, Hickenlooper, Luján, Padilla, Peters, Smith, Warnock, Markey, Merkley, Murray, Warren, and Welch. That's a fairly deep bench of Senate Democrats, though notably it's still an entirely Democratic coalition -- no Republican has signed on as a cosponsor.

That partisan lineup matters because it's the same pattern that sank the previous two attempts. Both earlier versions of CAOA, filed since 2022, stalled after being referred to committee and never got a floor vote in either chamber. There's no indication yet that this reintroduction has secured the Republican support needed to break that cycle in the Senate, where 60 votes would be required to overcome a filibuster.

Reform advocacy groups reacted with predictable enthusiasm -- NORML and the Drug Policy Alliance both praised the bill's reintroduction as a sign that full legalization remains a live legislative priority rather than a dead letter. But the reception on the other side of the Capitol has been much cooler. House Speaker Mike Johnson has previously spoken out against federal marijuana legalization, and with Republicans controlling the House, CAOA would face a steep climb even in the unlikely event it cleared the Senate. That combination -- a Democratic-only Senate bill and a Republican-controlled House leadership opposed to the concept -- is why most Capitol Hill observers view this reintroduction as a positioning move rather than a bill with a realistic near-term path to the president's desk.

The Trump Administration's Separate Rescheduling Track

Photo by Lucas Mosesson via Pexels.

While Senate Democrats were drafting their reintroduction, the Trump administration's own cannabis policy effort was already deep into a formal federal process. Trump signed an executive order on December 18, 2025 directing a review of marijuana's status under the Controlled Substances Act, setting the machinery in motion for what would become an administrative rescheduling push rather than a legislative one.

That review produced action in the spring. Acting Attorney General Todd Blanche issued an order on April 23, 2026 that immediately moved FDA-approved and state-licensed medical marijuana products to Schedule III. It's worth being precise about what that order actually did and didn't do: recreational cannabis remained classified as Schedule I under that same order. Rescheduling medical products to Schedule III is not the same thing as legalizing marijuana broadly, and the two get conflated in public conversation more often than they should.

The formal DEA hearing process examining this shift ran from June 29 to July 15, 2026, before Chief Administrative Law Judge Derek Julius, spanning more than two weeks of testimony from witnesses on both sides of the scheduling question. Judge Julius has now set August 17 as the deadline for post-hearing briefs, which can run up to 50 pages, before he issues a recommendation to the DEA Administrator on how to proceed.

Separately, three consolidated legal petitions challenging the April order have been pending before the D.C. Circuit Court of Appeals since May 29, with the Department of Justice's response to a related stay motion due July 2. That litigation adds another layer of uncertainty to a rescheduling process that was already going to take months to resolve even without a court fight running alongside it.

Why the Two Paths Don't Lead to the Same Place

Photo by Erik Mclean via Pexels.

It's tempting to treat rescheduling and full legalization as two roads to the same destination, but they aren't. Moving marijuana to Schedule III keeps it federally illegal for recreational use and leaves the entire Controlled Substances Act framework standing -- cannabis would still be a controlled substance, just one tier down, with all the federal criminal exposure that implies for anything outside FDA-approved or state-licensed medical channels.

CAOA's full descheduling approach eliminates that criminal exposure entirely and layers on tax, banking, and civil rights provisions that rescheduling has no mechanism to touch. As mgmagazine has noted, if CAOA were actually signed into law, it would render the DEA's ongoing rescheduling proceeding moot -- there would be nothing left to reschedule if marijuana isn't a controlled substance at all anymore.

The practical gaps are concrete. Schedule III status doesn't resolve the federal banking access problem that's kept most cannabis businesses on a cash-heavy, high-risk footing for years, and it doesn't touch the Section 280E tax burden that prevents state-licensed operators from deducting ordinary business expenses. CAOA's excise tax structure and its FinCEN banking directive are built specifically to address those two problems, which is precisely where Schedule III falls short.

The political math explains why these two tracks are moving at such different speeds. Rescheduling is an executive branch action -- Trump's DOJ and DEA can push it through largely on their own authority, subject to the administrative and judicial review already underway. CAOA needs 60 votes in the Senate and a majority in a Republican-controlled House that includes a sitting Speaker on record against federal legalization. One path runs through agency rulemaking; the other runs through a Congress that hasn't shown much appetite for it.

Rescheduling and full legalization aren't competing answers to the same question -- they're answers to two different questions. One is an administrative fix that adjusts where marijuana sits on a controlled-substances list while leaving federal prohibition largely intact for recreational use. The other rewrites federal drug law from the ground up, addressing taxation, banking, criminal records, and civil rights in ways an agency rule simply can't reach. Cannabis businesses and consumers shouldn't assume that movement on one track means the issue is settled, because progress on rescheduling wouldn't automatically resolve any of the questions CAOA is designed to answer, and vice versa.

Given the current makeup of the House and the Speaker's stated opposition to federal legalization, CAOA's reintroduction looks more like a marker of where Senate Democrats stand than a bill with a realistic shot at becoming law this session. That doesn't make it meaningless -- it keeps full legalization in the conversation and gives cosponsors something concrete to point to -- but it's not the thing to watch if you're trying to predict what changes on the ground in the next year.

That thing to watch is the DEA Administrator's eventual ruling following Judge Julius's recommendation, along with whatever the D.C. Circuit does with the pending petitions challenging the April order. Keep an eye on Senate committee activity too, in case CAOA gets further than its predecessors did. And regardless of what happens in Washington, federal status hasn't changed yet -- marijuana remains a controlled substance today, and readers should confirm the specific laws in their own state before acting on any of this, since state rules continue to vary widely and federal reform, whichever form it eventually takes, won't override that patchwork overnight.